In vitro modelling and therapeutic targeting of tumour cell migration in chronic lymphocytic leukaemia.
This programme continuity grant is funded by Blood Cancer UK. Tumour cells migrate to protective niches in the body to avoid destruction by conventional therapies. We are modelling this in the laboratory in order to identify the mechanisms tumour cells use to migrate.
Modelling and targeting Acute Myeloid Leukaemia cells in the bone marrow protective niche
This project grant is funded by a British Society of Haematology start-up grant and the Sussex Cancer Fund. Acute Myeloid Leukaemia is an aggressive disease with poor survival outcomes. The tumour cells remain anchored in the protective niche of the bone marrow where they can avoid destruction by conventional therapies.
Overcoming ibrutinib and venetoclax resistance in chronic lymphocytic leukaemia.
This project grant is funded by the Medical Research Council (MRC). Ibrutinib and venetoclax have revolutionised treatment of chronic lymphocytic leukaemia (CLL). However, they are non-curative and some patients remain refractory or develop resistance.
Preferential stem cell targeting using ProTide nucleoside analogues
This project grant is funded by the pharmaceutical company, Nucana. Although conventional anti-cancer approaches can frequently eradicate a large proportion of the bulk tumour, the most primitive stem cells are frequently chemo-resistant.